Urology and nephrology update: anemia of chronic kidney disease

Area of Science:

• Nephrology
• Hematology

Background:

• Anemia is prevalent across all stages of chronic kidney disease (CKD), becoming nearly universal in stage 5 CKD.
• Anemia in CKD is a diagnosis of exclusion, necessitating the investigation of other potential etiologies.
• Iron deficiency is frequently observed in CKD patients and impacts anemia management.

Purpose of the Study:

• To review the current understanding and management strategies for anemia in patients with chronic kidney disease.
• To highlight the importance of differential diagnosis and the role of iron in managing CKD anemia.
• To discuss treatment guidelines, challenges with erythropoiesis-stimulating agents, and emerging therapeutic options.

Main Methods:

• Literature review of current guidelines and research on anemia of CKD.
• Discussion of diagnostic approaches, including ruling out non-CKD causes of anemia.
• Analysis of treatment modalities, including iron supplementation, erythropoiesis-stimulating agents, and potential new therapies.

Main Results:

• Iron replenishment is crucial for improving anemia and response to erythropoiesis-stimulating agents in CKD.
• Current guidelines suggest a hemoglobin target of 11-12 g/dL, with lower levels acceptable for asymptomatic individuals.
• Some patients exhibit resistance or loss of response to erythropoiesis-stimulating agents, necessitating consideration of transfusions.

Conclusions:

• Effective management of anemia in CKD involves a comprehensive approach, including iron status assessment and consideration of alternative treatments.
• Vitamin C (ascorbic acid) is an emerging agent showing potential in managing anemia of CKD.
• Personalized treatment strategies are essential, as not all patients respond uniformly to current therapies.